Kane Biotech Inc (KNE) - Total Liabilities
Based on the latest financial reports, Kane Biotech Inc (KNE) has total liabilities worth CA$3.48 Million CAD (≈ $2.52 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Kane Biotech Inc growing its equity to track the company's year-over-year net asset growth rate.
Kane Biotech Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Kane Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See KNE free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Kane Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Kane Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marvel Discovery Corp
V:MARV
|
Canada | CA$1.86 Million |
|
Harris Technology Group Ltd
AU:HT8
|
Australia | AU$5.78 Million |
|
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
|
USA | $152.78 Million |
|
Socket Mobile Inc
NASDAQ:SCKT
|
USA | $10.35 Million |
|
MT Malcolm Mines NL
AU:M2M
|
Australia | AU$812.98K |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
Australia | AU$2.94 Million |
|
Alvo Minerals Ltd
AU:ALV
|
Australia | AU$471.67K |
|
Pembroke VCT PLC
LSE:PEMB
|
UK | GBX5.47 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Kane Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kane Biotech Inc (KNE) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kane Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kane Biotech Inc (2003–2025)
The table below shows the annual total liabilities of Kane Biotech Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$3.48 Million ≈ $2.52 Million |
-15.59% |
| 2024-12-31 | CA$4.12 Million ≈ $2.98 Million |
-70.74% |
| 2023-12-31 | CA$14.09 Million ≈ $10.19 Million |
+44.40% |
| 2022-12-31 | CA$9.76 Million ≈ $7.06 Million |
+26.70% |
| 2021-12-31 | CA$7.70 Million ≈ $5.57 Million |
+94.43% |
| 2020-12-31 | CA$3.96 Million ≈ $2.87 Million |
+106.42% |
| 2019-12-31 | CA$1.92 Million ≈ $1.39 Million |
-24.48% |
| 2018-12-31 | CA$2.54 Million ≈ $1.84 Million |
+285.53% |
| 2017-12-31 | CA$659.03K ≈ $476.74K |
-15.91% |
| 2016-12-31 | CA$783.72K ≈ $566.93K |
+13.11% |
| 2015-12-31 | CA$692.86K ≈ $501.21K |
+4.27% |
| 2014-12-31 | CA$664.51K ≈ $480.70K |
+10.69% |
| 2013-12-31 | CA$600.31K ≈ $434.26K |
+239.68% |
| 2012-12-31 | CA$176.73K ≈ $127.84K |
+90.59% |
| 2011-12-31 | CA$92.72K ≈ $67.08K |
+2.18% |
| 2010-12-31 | CA$90.75K ≈ $65.65K |
+32.25% |
| 2009-12-31 | CA$68.62K ≈ $49.64K |
-13.76% |
| 2008-12-31 | CA$79.56K ≈ $57.55K |
-9.44% |
| 2007-12-31 | CA$87.86K ≈ $63.56K |
-5.36% |
| 2006-12-31 | CA$92.83K ≈ $67.16K |
-31.04% |
| 2005-12-31 | CA$134.62K ≈ $97.38K |
+35.00% |
| 2004-12-31 | CA$99.72K ≈ $72.14K |
+74.88% |
| 2003-12-31 | CA$57.02K ≈ $41.25K |
-- |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more